Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $8.03 per share in its upcoming release, pointing to a year-over-year decline of 30.5%. It is anticipated that ...

Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...

John G Ullman & Associates Inc. made a hefty bet on Regeneron Pharmaceuticals, upping their stake by a whopping 94%, now ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

We just received data on a new analyst forecast for $ING. Barclays gave a rating of 'Overweight' for $ING.